| Name | Bisacodyl |
| Description | Bisacodyl (Fenilaxan) is a diphenylmethane stimulant laxative used for the treatment of constipation and for bowel evacuation. |
| In vitro | Bisacodyl inhibits the absorption of water in rats' jejunum, ileum, and colon, with the degree of inhibition linearly correlated to the logarithm of bisacodyl concentration. At a dosage of 4.3 mg/kg, bisacodyl, in combination with AOM, increases the number of microcysts per colony in rats without increasing tumor numbers. However, a higher dosage of 43 mg/kg significantly raises both the microcyst and tumor counts. Compared to rats treated with saline, bisacodyl (5.9 mg/kg) significantly reduces the activity of jejunum and colon (Na + K) ATPases. Furthermore, at 5.9 mg/kg, bisacodyl markedly increases PGE2 levels and stimulates adenylate cyclase activity in the jejunum and colon, without affecting cAMP levels. Oral administration of 10 mg/kg bisacodyl significantly decreases NOS activity in the rat jejunum. Meanwhile, 20 mg/kg bisacodyl leads to a reduction in AQP3 protein expression and an increase in TNF-α mRNA expression levels in the rat colon. |
| In vivo | At a concentration of 10 μg/mL, Bisacodyl acts on Raw264.7 cells, leading to an increase in the mRNA expression levels of TNF-α, COX2, and PGE2. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 55 mg/mL (152.19 mM), Sonication is recommended.
Ethanol : < 1 mg/mL (insoluble or slightly soluble)
|
| Keywords | Inhibitor | Opioid Receptor | Dopamine Transporter | DAT | Bisacodyl | inhibit | SLC6A3 |
| Related Compound Libraries | FDA-Approved & Pharmacopeia Drug Library | Bioactive Compound Library | Drug-induced Liver Injury (DILI) Compound Library | Drug Repurposing Compound Library | NO PAINS Compound Library | FDA-Approved Drug Library | Orally Active Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Human Metabolite Library |
United States
